Three years af­ter un­der­whelm­ing da­ta, Lieping Chen's NextCure drops lead pro­gram

The hints were there for NextCure. A No­vem­ber 2019 da­ta drop at SITC that un­der­whelmed. And then aca­d­e­m­ic founder Lieping Chen launch­ing an­oth­er biotech.

Two weeks ago, PD-L1 pi­o­neer Chen moved on to his next big biotech ven­ture, with the pub­lic re­veal­ing of Nor­mu­ni­ty. Now, his oth­er Yale spin­out, NextCure, is ad­just­ing plans. The Mary­land drug de­vel­op­er said af­ter Thurs­day’s clos­ing bell that it would stop work­ing on its lead pro­gram, known as NC318.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER